Filing Flows

Filing Flows › Lyell Immunopharma (LYEL) › Next earnings date

Lyell Immunopharma (LYEL) earnings: beat the estimate

Lyell Immunopharma (LYEL) reported on Nov 4, 2026 and beat the EPS estimate: −$1.69 against −$1.88 (+10.1%). Revenue was $3K for Q3 2026, -80% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+10.1% vs estimate
Beat rate80%

The last report

Lyell Immunopharma reported revenue of $3K for the third quarter 2026 (-80% Y/Y), net loss $45.5M. How it makes money → · Every quarter →

Lyell Immunopharma: EPS against the estimate, last 5 reportsLyell Immunopharma: EPS against the estimate, last 5 reportsEstimateReported−$2.64−$2.13Nov 25−$2.23−$7.68Mar 26−$2.36−$1.10May 26−$1.79−$1.74Aug 26−$1.88−$1.69Nov 26
Latest (Nov 26): Estimate −$1.88, Reported −$1.69.

Lyell Immunopharma's latest quarter

Lyell Immunopharma, Q3 2026: revenue $3K (-80% year over year), net loss $45.5M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.

Questions

Did Lyell Immunopharma beat earnings?

Lyell Immunopharma (LYEL) reported on Nov 4, 2026 and beat the EPS estimate: −$1.69 against −$1.88 (+10.1%).

When does LYEL report earnings?

The next date is not set yet.

Does Lyell Immunopharma usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.